Novavax Inc.

182.72+3.39+1.89%Vol 2.72M1Y Perf 28.38%
Aug 2nd, 2021 16:00 DELAYED
BID182.72 ASK185.00
Open183.82 Previous Close179.33
Pre-Market- After-Market182.90
 - -  0.18 0.10%
Target Price
249.60 
Analyst Rating
Strong Buy 1.50
Potential %
36.60 
Finscreener Ranking
     40.56
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     34.49
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★     44.03
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap13.54B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
41.60 
Earnings Date
5th Aug 2021

Today's Price Range

177.17186.50

52W Range

76.59331.68

5 Year PE Ratio Range

-1.90-1.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
2.07%
1 Month
-15.88%
3 Months
-6.36%
6 Months
-35.71%
1 Year
28.38%
3 Years
680.85%
5 Years
20.05%
10 Years
431.16%

TickerPriceChg.Chg.%
NVAX182.723.39001.89
AAPL145.52-0.3400-0.23
GOOG2 719.7915.37000.57
MSFT284.82-0.0900-0.03
XOM57.580.01000.02
WFC45.79-0.1500-0.33
JNJ172.270.07000.04
FB351.95-4.3500-1.22
GE100.60-3.0000-2.90
JPM151.17-0.6100-0.40
Financial StrengthValueIndustryS&P 500US Markets
1.70
1.90
0.25
0.44
-35.10
Leverage Ratio 2.50
ProfitabilityValueIndustryS&P 500US Markets
-
-64.70
-64.00
-750.20
-67.07
RevenueValueIndustryS&P 500US Markets
883.91M
11.93
129.94
75.55
Earnings HistoryEstimateReportedSurprise %
Q01 2021-2.65-3.05-15.09
Q04 2020-1.53-2.70-76.47
Q03 20202.36-3.21-236.02
Q02 2020-0.57-0.3047.37
Q01 2020-0.67-0.5813.43
Q04 2019-1.08-1.13-4.63
Q03 2019-1.02-1.03-0.98
Q02 2019-1.61-1.69-4.97
Earnings Per EndEstimateRevision %Trend
6/2021 QR-3.76-251.00Negative
9/2021 QR-3.03-136.86Negative
12/2021 FY-6.42-125.33Negative
12/2022 FY30.21-8.01Negative
Next Report Date5th Aug 2021
Estimated EPS Next Report-3.76
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume2.72M
Shares Outstanding74.09M
Trades Count42.82K
Dollar Volume584.33M
Avg. Volume4.12M
Avg. Weekly Volume2.80M
Avg. Monthly Volume3.58M
Avg. Quarterly Volume4.16M

Novavax Inc. (NASDAQ: NVAX) stock closed at 182.72 per share at the end of the most recent trading day (a 1.89% change compared to the prior day closing price) with a volume of 2.74M shares and market capitalization of 13.54B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 522 people. Novavax Inc. CEO is Stanley Charles Erck.

The one-year performance of Novavax Inc. stock is 28.38%, while year-to-date (YTD) performance is 63.86%. NVAX stock has a five-year performance of 20.05%. Its 52-week range is between 76.59 and 331.68, which gives NVAX stock a 52-week price range ratio of 41.60%

Novavax Inc. currently has a PE ratio of -19.00, a price-to-book (PB) ratio of 12.79, a price-to-sale (PS) ratio of 15.32, a price to cashflow ratio of 18.00, a PEG ratio of 2.32, a ROA of -41.60%, a ROC of -62.39% and a ROE of -121.37%. The company’s profit margin is -67.07%, its EBITDA margin is -64.00%, and its revenue ttm is $883.91 Million , which makes it $11.93 revenue per share.

Of the last four earnings reports from Novavax Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-3.76 for the next earnings report. Novavax Inc.’s next earnings report date is 05th Aug 2021.

The consensus rating of Wall Street analysts for Novavax Inc. is Strong Buy (1.5), with a target price of $249.6, which is +36.60% compared to the current price. The earnings rating for Novavax Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Novavax Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Novavax Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 25.87, ATR14 : 14.70, CCI20 : -80.73, Chaikin Money Flow : -0.19, MACD : -1.00, Money Flow Index : 56.17, ROC : 0.86, RSI : 43.12, STOCH (14,3) : 12.43, STOCH RSI : 0.06, UO : 36.45, Williams %R : -87.57), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Novavax Inc. in the last 12-months were: Gary C. Evans (Option Excercise at a value of $908 930), Gary C. Evans (Sold 46 125 shares of value $8 425 339 ), Gregory M. Glenn (Option Excercise at a value of $4 819 737), Gregory M. Glenn (Sold 146 656 shares of value $22 040 666 ), James F. Young (Option Excercise at a value of $885 438), James F. Young (Sold 10 000 shares of value $2 282 231 ), John A. Herrmann (Option Excercise at a value of $5 666 370), John A. Herrmann (Sold 204 481 shares of value $28 697 260 ), John J. Trizzino (Option Excercise at a value of $10 371 353), John J. Trizzino (Sold 411 769 shares of value $54 098 298 ), Michael A. Mcmanus (Option Excercise at a value of $220 800), Michael A. Mcmanus (Sold 20 000 shares of value $3 219 110 ), Rachel K. King (Option Excercise at a value of $0), Richard Douglas (Option Excercise at a value of $0), Stanley Charles Erck (Option Excercise at a value of $9 572 027), Stanley Charles Erck (Sold 195 940 shares of value $31 525 248 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (75.00 %)
6 (85.71 %)
5 (71.43 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (25.00 %)
1 (14.29 %)
2 (28.57 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.29
Moderate Buy
1.57

Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

CEO: Stanley Charles Erck

Telephone: +1 240 268-2000

Address: 21 Firstfield Road, Gaithersburg 20878, MD, US

Number of employees: 522

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

83%17%

Bearish Bullish

56%44%

Bearish Bullish

46%54%

News

Stocktwits